Impact of maternal infection with hepatitis B virus on pregnancy complications and neonatal outcomes for women undergoing assisted reproductive technology treatment: A population‐based study

• Published in: Journal of viral hepatitis Vol. 28; no. 4; pp. 613 - 620
• Main Authors: Xiong, Yiquan, Liu, Chunrong, Huang, Shiyao, Wang, Jing, Qi, Yana, Yao, Guanhua, Sun, Wei, Qian, Yongyao, Ye, Lishan, Liu, Hui, Xu, Qiushi, Zou, Kang, Tan, Jing, Sun, Xin
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.04.2021
• Subjects: Antigens; assisted reproduction technology; Birth weight; Cholestasis; Diabetes mellitus; Eclampsia; HBsAg; HBV; Hepatitis B; Hepatitis B e antigen; Hepatitis B surface antigen; hepatitis B virus; Infections; Neonates; Placenta; Population studies; Population-based studies; pregnancy complication; Pregnancy complications; Premature birth; Reproductive technologies; HBsAg; pregnancy complication; assisted reproduction technology; HBV; hepatitis B virus
• ISSN: 1352-0504; 1365-2893
• DOI: 10.1111/jvh.13472

The aim of this study was to investigate the impact of maternal hepatitis B virus (HBV) status on pregnancy complications and neonatal outcomes for women undergoing assisted reproductive technology (ART). A total of 7,011 pregnancies achieved by ART were included from a population‐based database involving 523,111 pregnancies. Exposures of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) among pregnant women were routinely tested at the first antenatal visit for all pregnancies. We collected pregnancy complications (e.g., gestational diabetes mellitus [GDM], intrahepatic cholestasis of pregnancy [ICP]), neonatal outcomes and confounding variables from the same database. Univariate and multivariate analyses by adjusting confounders were conducted to evaluate the impact of maternal HBV infection. Prevalence of HBsAg seropositivity (HBsAg+) was 11.34% (95% CI 10.6–12.1) and that of HBsAg and HBeAg co‐seropositivity (HBsAg+HBeAg+) was 2.55% (2.1–3.0) among included population. Compared with HBsAg−group, ICP risk in the HBsAg+group was higher (4.03% vs. 1.79%; adjusted odds ratio [aOR] 2.49, 1.65−3.77). Similarly, ICP prevalence in the HBsAg+HBeAg+ group was higher than that in the HBsAg−HBeAg− group (6.47% vs. 1.61%; aOR 4.78, 2.28–9.98). No associations were found between maternal HBV infection (i.e., HBsAg+, HBsAg+HBeAg+, or HBsAg+HBeAg−) and other adverse outcomes for women undergoing ART (i.e., GDM, pre‐eclampsia, placental previa, premature separation of placenta, premature rupture of membranes, preterm birth and low birthweight) in this study. In conclusion, maternal HBV infection (HBsAg+or HBsAg+HBeAg+) probably increase ICP risk, but may not associate with other pregnancy complications or neonatal outcomes for pregnant women who underwent ART.